Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: Implication for prostate cancer risk

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 4, 2004, Pages 333-337

  Kakinuma, H ^a   Tsuchiya, N ^a   Habuchi, T ^a   Ohyama, C ^a   Matsuura, S ^a   Wang, L ^a   Nakamura, A ^a   Kato, T ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP17 gene; Polymorphism; SRD5A2 gene; Steroid hormones

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CYTOCHROME P450 17; ESTRADIOL; NUCLEIC ACID; ONCOPROTEIN; PRASTERONE SULFATE; PROTEIN SRD5A2; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; DNA; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANDROGENS; ANDROSTENEDIONE; COHORT STUDIES; DNA, NEOPLASM; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR MARKERS, BIOLOGICAL;

EID: 16644386946     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500753     Document Type: Article

References (28)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
3. Ross R et al. Serum testosterone levels in healthy young black and white men 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. J Natl Cancer Inst 1986; 76: 45-48.
4. Ross RK et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-889.
5. de Jong FH et al. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: Results from the Dutch-Japanese case-control study. Cancer Res 1991; 51: 3445-3450.
6. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000; 18: 847-853.
7. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727-1731.
8. Gsur A et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 434-437.
9. Wadelius M et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635-639.
10. Haiman CA et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 743-748.
11. Habuchi T et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710-5713.
12. Febbo PG et al. The V89L polymorphism in the 5 alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999; 59: 5878-5881.
13. Nam RK et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57: 199-204.
14. Hsing AW et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 1077-1082.
15. Makridakis N et al. A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase. Cancer Res 1997; 57: 1020-1022.
16. Li Z et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 2003; 169: 2378-2381.
17. Carey AH et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873-1876.
18. Feigelson HS et al. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 585-587.
19. Haiman CA et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999; 59: 1015-1020.
20. Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: A meta-analysis. Mutagenesis 2002; 17: 119-126.
21. Feigelson HS et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. The CYP17 MspA1 polymorphism and breast cancer risk: A meta-analysis. Cancer Res 1997; 57: 1063-1065.
22. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5 alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 185-189.
23. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976; 57: 1093-1097.
24. Gann PH et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118-1126.
25. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 1992; 74: 939-942.
26. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000; 10: 407-413.
27. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994; 86: 252-254.
28. Oishi K, Yoshida O, Schroeder FH. The geography of prostate cancer and its treatment in Japan. Cancer Surv 1995; 23: 267-280.